Recruiting Ulcerative Colitis Studies in Aurora
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno ...
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and eff...
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is...
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspecte...
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC)....
NS-050/NCNP-03 in Boys With DMD (Meteor50)
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly...
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skip...
About Ulcerative Colitis Clinical Trials in Aurora
Ulcerative colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in the innermost lining of the colon and rectum. It typically presents with bloody diarrhea, abdominal pain, and urgency. Treatment includes aminosalicylates, corticosteroids, immunosuppressants, and biologics.
There are currently 7 ulcerative colitis clinical trials recruiting participants in Aurora, ILLINOIS. These studies are seeking a combined 465 participants. Research is being sponsored by AbbVie, REGENXBIO Inc., Veralox Therapeutics and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ulcerative Colitis Clinical Trials in Aurora — FAQ
Are there ulcerative colitis clinical trials in Aurora?
Yes, there are 7 ulcerative colitis clinical trials currently recruiting in Aurora, ILLINOIS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Aurora?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.
Are clinical trials in Aurora free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.
What ulcerative colitis treatments are being tested?
The 7 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for ulcerative colitis.
Data updated March 2, 2026 from ClinicalTrials.gov